RT Journal Article
SR Electronic
T1 Health-related Quality of Life and Toxicity After Single-fraction High-dose-rate Brachytherapy With External Beam Radiotherapy for Localized and Locally Advanced Prostate Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 477
OP 486
DO 10.21873/anticanres.13137
VO 39
IS 1
A1 TOMOYUKI MAKINO
A1 KAZUFUMI NAKASHIMA
A1 MASASHI IIJIMA
A1 SHOUHEI KAWAGUCHI
A1 TAKAHIRO NOHARA
A1 KAZUYOSHI SHIGEHARA
A1 KOUJI IZUMI
A1 YOSHIFUMI KADONO
A1 TOMOYASU KUMANO
A1 ATSUSHI MIZOKAMI
YR 2019
UL http://ar.iiarjournals.org/content/39/1/477.abstract
AB Background/Aim: To evaluate the treatment outcomes, toxicity and health-related quality of life (HRQOL) in prostate cancer (PCa) patients who underwent single-fraction high-dose-rate brachytherapy (single-fraction HDR-BT) with external beam radiotherapy (EBRT). Materials and Methods: From April 2014 to October 2017, treatment outcomes and toxicity of 85 patients who underwent single-fraction HDR-BT of 13 Gy, followed by 46 Gy EBRT in 23 fractions, were examined. HRQOL of 53 patients was evaluated using the Expanded Prostate Cancer Index Composite (EPIC), International Prostate Symptom Score (IPSS)/QOL index, International Index of Erectile Function 5 (IIEF-5), and 36-Item Short Form Survey (SF-36) scores through one year. Results: The median follow-up period was 28.8 months. Only three patients had biochemical recurrence. Toxicities included less than grade 3 lower urinary tract symptoms and grade 1 diarrhea. Urethral stricture, a problem related to late toxicity in conventional HDR-BT, was not observed. The urinary and bowel functions in EPIC scores significantly worsened until three or six months after treatment, respectively. Conclusion: Single-fraction HDR-BT with EBRT showed promising biochemical control, tolerant toxicities, and preservation of HRQOL, and can be efficiently performed in a shorter time than conventional HDR-BT.